Designed with patients in mind1
The YUSIMRY autoinjector pen offers simple and reliable performance1
The YUSIMRY pen is designed to support self-administration.1 For administration instructions, please review the Instructions for Use included in the YUSIMRY prescribing information.
The Autoinjector Experience
See how the autoinjector pen works.
Citrate-free formulation may reduce pain during and following injection.2
Latex-free material3
Identical dosing schedule to low-concentration HUMIRA3,4
Dosing Information by indication
Select a disease state below to learn more about dosing requirements.
Juvenile Idiopathic Arthritis (JIA)
Pediatric Patients 2 years of Age and Older Weighing 30 kg (66 lbs) or Greater: 40 mg every other week.
There is no dosage form for YUSIMRY that allows weight-based dosing for pediatric patients below 30 kg.3
Psoriatic Arthritis (PsA)
Adults: 40 mg every other week.
• Some patients with PsA not receiving methotrexate may benefit from increasing the dosage to 40 mg every week or 80 mg every other week.3
Ankylosing Spondylitis (AS)
Adults: 40 mg every other week.
• Some patients with AS not receiving methotrexate may benefit from increasing the dosage to 40 mg every week or 80 mg every other week.3
Crohn’s Disease (CD)
Adults: 160 mg on Day 1 (given in one day or split over two consecutive days); 80 mg on Day 15; and 40 mg every other week starting on Day 29.3
Pediatric Patients 6 Years of Age and Older Weighing 40 kg (88 lbs) or Greater: 160 mg on Day 1 (given in single dose or split over two consecutive days); 80 mg on Day 15; and 40 mg every other week starting on Day 29.3
Ulcerative Colitis (UC)
Adults: 160 mg on Day 1 (given in one day or split over two consecutive days), 80 mg on Day 15 and 40 mg every other week starting on Day 29. Discontinue in patients without evidence of clinical remission by eight weeks (Day 57).3
Plaque Psoriasis (Ps)
Adults: 80 mg initial dose, followed by 40 mg every other week starting one week after initial dose.3
Hidradenitis Suppurativa (HS)
Adults:
• Day 1: 160 mg (given in one day or split over two consecutive days)3
• Day 15: 80 mg3
• Day 29 and subsequent doses: 40 mg every week or 80 mg every other week3
REFERENCES:
1. Design Validation, Coherus BioSciences, Inc. Data on file. 2. Nash P, Vanhoof J, Hall S, et al. Randomized crossover comparison of injection site pain with 40 mg/0.4 or 0.8 mL formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther. 2016;3:257-270. 3. YUSIMRY™ (adalimumab-aqvh) prescribing information. Coherus BioSciences, Inc. 4. Humira (adalimumab) prescribing information. AbbVie Inc.